Icatibant (acetate) (Standard)

CC(O)=O.O=C([C@@H]1N(CC2=CC=CC=C2C1)C([C@H](CO)NC([C@@H](NC(CNC([C@H]3N(C[C@H](O)C3)C([C@H]4N(CCC4)C([C@H](CCCNC(N)=N)NC([C@H](N)CCCNC(N)=N)=O)=O)=O)=O)=O)CC5=CC=CS5)=O)=O)N6[C@]7([H])[C@](CCCC7)([H])C[C@H]6C(N[C@H](C(O)=O)CCCNC(N)=N)=O

[1]Hock FJ, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol. 1991 Mar;102 (3) :769-73.|[2]Y Arai, et al. Effect of Icatibant, a Bradykinin B2 Receptor Antagonist, on the Development of Experimental Ulcerative Colitis in Mice. Dig Dis Sci. 1999 Apr;44 (4) :845-51.|[3]Marie-Thérèse Bawolak, et al The Bradykinin B2 Receptor Antagonist Icatibant (Hoe 140) Blocks Aminopeptidase N at Micromolar Concentrations: Off-Target Alterations of Signaling Mediated by the Bradykinin B1 and Angiotensin Receptors. Eur J Pharmacol. 2006 Dec 3;551 (1-3) :108-11.|[4]Hock FJ, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol. 1991 Mar;102 (3) :769-73.|[5]Y Arai, et al. Effect of Icatibant, a Bradykinin B2 Receptor Antagonist, on the Development of Experimental Ulcerative Colitis in Mice. Dig Dis Sci. 1999 Apr;44 (4) :845-51.|[6]Marie-Thérèse Bawolak, et al The Bradykinin B2 Receptor Antagonist Icatibant (Hoe 140) Blocks Aminopeptidase N at Micromolar Concentrations: Off-Target Alterations of Signaling Mediated by the Bradykinin B1 and Angiotensin Receptors. Eur J Pharmacol. 2006 Dec 3;551 (1-3) :108-11.